#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	28658	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2172	1298.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1466	1466	C	1624	C,A,T	1559,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	52060	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3708	1387.2	0	.	n	.	0	T695C	SNP	695	695	T	1010	1010	C	1648	C,T	1576,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	52060	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3708	1387.2	0	.	n	.	0	A1638G	SNP	1638	1638	A	1953	1953	G	1626	G,T	1557,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	52060	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3708	1387.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2286	2286	C	1645	C,A	1561,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	52060	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3708	1387.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2360	2360	A	1604	A	1541	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	52060	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3708	1387.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2912	2912	C	1647	C	1586	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	3388	folP	855	855	100.0	folP.l15.c4.ctg.1	1601	209.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1063	1065	AGC	344;344;347	A;G;C	328;329;329	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	9076	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3534	253.4	1	SNP	p	S91F	1	.	.	271	273	TTC	606	608	TTC	314;316;314	T;T;C	300;304;300	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	9076	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3534	253.4	1	SNP	p	D95G	1	.	.	283	285	GGC	618	620	GGC	311;310;306	G;G;C	301;300;297	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	9076	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3534	253.4	1	SNP	p	G95N	0	.	.	283	285	GGC	618	620	GGC	311;310;306	G;G;C	301;300;297	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	27	3016	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1330	223.4	1	SNP	p	G45D	0	.	.	133	135	GGC	416	418	GGC	367;365;364	G;G;C	353;356;355	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1550	mtrR_promoter	250	250	99.21	mtrR_promoter.l15.c4.ctg.1	860	175.2	0	.	n	.	0	.206TT	INS	206	206	T	549	549	T	342	T	329	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	8920	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3079	286.1	1	SNP	p	D86N	0	.	.	256	258	GAC	622	624	GAC	339;338;340	G;A;C	324;314;327	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	8920	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3079	286.1	1	SNP	p	R87W	0	.	.	259	261	CGT	625	627	CGT	340;338;339	C;G;T	325;324;317	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	8920	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3079	286.1	1	SNP	p	R87I	0	.	.	259	261	CGT	625	627	CGT	340;338;339	C;G;T	325;324;317	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	8920	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3079	286.1	1	SNP	p	S87R	1	.	.	259	261	CGT	625	627	CGT	340;338;339	C;G;T	325;324;317	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	8920	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3079	286.1	1	SNP	p	S88P	0	.	.	262	264	TCC	628	630	TCC	339;340;341	T;C;C	323;323;325	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	7218	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2678	265.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1627	1629	GGC	381;370;371	G;G;C	365;352;347	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1298	1300	GCA	416;413;416	G;C,A;A	401;392,1;403	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1301	1303	ATC	419;417;416	A;T;C	400;400;400	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1313	1315	GTG	422;422;425	G;T;G	403;399;410	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1313	1315	GTG	422;422;425	G;T;G	403;399;410	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1817	1819	ACC	338;338;335	A;C;C	320;324;325	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1871	1873	GCG	314;313;314	G;C,G;G,C	297;263,2;289,2	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1871	1873	GCG	314;313;314	G;C,G;G,C	297;263,2;289,2	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1994	1996	AGC	273;273;268	A;G;C	266;265;263	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2003	2005	GGC	265;265;263	G;G;C	258;257;253	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	7118	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2317	301.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2021	2023	CCG	225;228;226	C,G;C,G;G,C	182,9;187,5;189,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	10444	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3067	335.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1600	1602	CCG	341;341;343	C;C;G	315;329;322	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	4264	porA	1146	1146	99.91	porA.l15.c30.ctg.1	1748	239.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	581	581	C	302	C	291	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	391	393	GAA	412;411;408	G;A;A	392;393;393	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	A74V	NONSYN	220	222	GCC	499	501	GTC	400;395;394	G;T,C,G;C	386;352,1,1;375	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	679	681	GAT	404;406;409	G,A;A;T,A	387,3;386;389,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	802	804	TCA	376;372;372	T,G;C;A	354,1;355;355	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	931	933	GTC	427;427;425	G,T;T;C	413,1;400;416	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	F222Y	NONSYN	664	666	TTT	943	945	TAT	410;414;415	T;A,T;T	403;400,1;408	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1261	1263	GCA	431;427;429	G;C;A	414;409;415	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	1	SNP	p	G120K	1	.	.	358	360	AAG	637	639	AAG	389;389;396	A;A,C;G	378;375,1;380	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	1	SNP	p	D121N	0	.	.	361	363	GAC	640	642	GAC	396;391;388	G,A;A;C	383,1;374;378	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	5162	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1468	345.6	1	SNP	p	A121D	1	.	.	361	363	GAC	640	642	GAC	396;391;388	G,A;A;C	383,1;374;378	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	18316	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4828	374.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	2080	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1089	188.4	1	SNP	p	V57M	1	.	.	169	171	ATG	543	545	ATG	419;421;422	A;T;G	407;407;409	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
